Atherosclerosis Risk — ApoE Genotyping

A genetic test that determines your Apolipoprotein E (ApoE) genotype — the inherited variant of a protein central to cholesterol transport. ApoE status is associated with how your body handles cholesterol and with long-term cardiovascular and neurological risk, so it complements (rather than replaces) standard cholesterol bloods. The test requires signed informed consent and takes about a week to return. Drawn at the ISO 15189-accredited Brno-Starý Lískovec laboratory.

Riziko aterosklerózy (Atherosclerosis Risk) is a genetic self-pay test that determines your Apolipoprotein E (ApoE) genotype. ApoE is a protein with a central role in transporting cholesterol and other lipids around the body, and the particular variant a person inherits is associated with differences in cholesterol levels and in long-term cardiovascular and neurological risk. Because it reads an inherited trait rather than a current biochemical value, the ApoE genotype does not change over time — making it a one-off piece of information that adds context to repeat lipid testing and to family-history discussions. This test is genetic, so Lab Med requires written informed consent before the sample is taken. The sample itself is a standard venous blood draw of around fifteen minutes, taken on a walk-in basis between 07:00 and 11:00, Monday to Friday, at the second-floor collection room of the Poliklinika U Pošty in Brno-Starý Lískovec; fasting is not specifically required for the genotyping, but follow the collection conditions confirmed at booking. All sampling material is provided free of charge. Because this is a molecular analysis rather than a routine biochemistry test, the turnaround is longer than most packages — approximately one week. Results are collected in person against signature and ID, or via secure electronic delivery set up at the collection room. An ApoE genotype is most useful when interpreted alongside measured lipids (for example from the Lipid Metabolism or Atherosclerosis panels) and a clinician's view of overall risk; it is a predisposition marker, not a diagnosis, and given its associations with neurological as well as cardiovascular risk, the result is best discussed with a physician who can explain what it does and does not mean for the individual. The analysis is performed in a laboratory accredited to ČSN EN ISO 15189.